AUTHORS
Thura Win Htut, MD, FRCPath, J. Savoy2, Alexis Geppner, BS, MS, BSMedTech, MT, PA-C3, Gautham Borthakur4, Nitin Jain, MD5, Fadi G. Haddad, MD6, Yesid Alvarado7, Abhishek Maiti, MBBS8, Maro Ohanian, DO9, Elias Jabbour, MD10, Alessandra Ferrajoli III, MD11, Hagop Kantarjian, MD12, Farhad Ravandi, MD13, Guillermo Garcia-Manero, MD14, Tapan Kadia I, MD15
AFFILIATIONS
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
13 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
15 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
ABSTRACT
Background
T-cell large granular lymphocytic leukemia (T-LGL) is a chronic lymphoproliferative disorder associated with cytopenias and autoimmune manifestations. Immunosuppressive therapies including methotrexate, cyclophosphamide, and cyclosporine represent standard treatment approaches; however, response rates are modest and therapeutic options for patients (pts) with relapsed or refractory (RR) disease remain limited. Alemtuzumab, an anti-CD52 monoclonal antibody, has activity in T-LGL, but real-word data regarding its efficacy, kinetics of response, durability, supportive-care independence and safety in heavily pretreated pts are limited.
Methods
We analyzed pts with T-LGL treated with alemtuzumab at our institution from 2011-2026. Clinical, hematologic, genomic, treatment, response, and safety characteristics were collected. All pts received alemtuzumab 10 mg IV daily for 10 doses. Hematologic responses were assessed using Loughran response criteria and categorized as complete response (CR), partial response (PR), no response (NR), progressive disease (PD), or not evaluable (NE). Time to first and best response were calculated from alemtuzumab initiation. Time to next treatment (TTNT) was calculated from alemtuzumab initiation to subsequent therapy. Safety included grade 3-4 infections, lymphopenia, infusion reactions, viral reactivation and hospitalization.
Results
A total of 16 pts was identified, with a median age at alemtuzumab initiation of 64.5 years (range, 27- 83) of whom 56% were male. Pts received a median of 2 prior lines of therapy, (range,1-4), including cyclosporine in 75%, methotrexate in 56%, cyclophosphamide in 38%, and rituximab in 25%. 88% of pts were previously treated with corticosteroids. At baseline, 81% had anemia, 56% neutropenia, and 19% thrombocytopenia; 31% had a diagnosis of pure red cell aplasia. Red cell transfusion dependence was reported in 12 pts (75%) while 44% required G-CSF support. STAT3 mutations were identified in 7 of 15 (47%) evaluable pts.
All 16 pts were toxicity-evaluable and 15 response-evaluable. Pts. The best ORR was 67% (10/15) including CR in 47% (7/15) and PR in 20% (3/15). Median time to first response among responders was 1.7 months (range, 0.2 to 5.3). Median time to best response was 3.3 months (0.7-12.2). At 3 months landmark, the ORR was 43% (6/14 evaluable), including CR in 29% and PR in 14%; at 6 months landmark, 13 pts were evaluable and the ORR was 38% (5/13), including CR in 23% and PR in 15%, with fewer evaluable pts at later landmarks due to shorter-follow up. Among 15 evaluable pts, red cell transfusion independence was achieved in 45% (5/11) and 50% (5/10) of evaluable pts at 3 and 6 months, respectively, while GCSF independence was 40% (4/10) and 57% (4/7).
At a median follow-up of 43.2 months, 1- and 2- year OS rates were 92.3% and 83.1%. Median EFS in 15 evaluable pts was 12.1 months (95% CI, 3.4-NA) with 1-and 2-year EFS rates of 50.6% and 28.9% respectively. Among 9 pts who received subsequent therapy, the median TTNT was 10.5 months (range, 0.3-45.9).
All pts received antiviral prophylaxis with valacyclovir while pneumocystis jirovecii pneumonia, antibacterial, and antifungal prophylaxis were administered in 94%, 88%, and 88% of pts, respectively. Grade 3-4 lymphopenia occurred in 81%, and grade 1-2 infusion reaction in 25%. Grade 3-4 infections occurred in 38% (6/16), and were predominantly viral in etiology (5/6, 83%) including influenza A, adenovirus, cytomegalovirus (CMV), human metapneumovirus, and another respiratory viral infection; Asymptomatic CMV reactivation occurred in 13% (2/16), with both pts requiring treatment with prompt resolution; no EBV reactivation was observed. Six pts (38%) required infection-related hospitalization and 2 (13%) required ICU admission for type 1 respiratory failure following pneumonia, including COVID infection.
Conclusions
Alemtuzumab demonstrated clinically meaningful activity in heavily pretreated pts with T-LGL, achieving a ORR of 67% and a CR rate of 47%, with rapid responses and achievement of red cell transfusion dependence in 50 % of evaluable pts at 6 months after treatment initiation. Despite a median EFS of 12.1 months, 1- and 2- year OS remained favorable at longer-term follow-up. Despite antimicrobial prophylaxis, lymphopenia and grade 3/4 infections were frequent but manageable, warranting vigilant monitoring. These findings support alemtuzumab for selected pts with RR T-LGL.
DISCLOSURES
Thura Win Htut, MD, FRCPath: No relevant conflicts of interest to declare.